The genetic material (DNA or RNA) of viral pathogens contains enzymes called viral proteases. Viral proteases catalyze the cleavage of particular peptide bonds in cellular proteins or viral polyprotein precursors. Viral proteases may attack the scissile peptide bond using various catalytic mechanisms involving either serine, cysteine, or aspartic acid residues. A high degree of specific recognition and cleavage is guaranteed by the enzyme's complementary substrate binding site's selective recognition of these sequence patterns.
The respiratory illness coronavirus disease 2019 (COVID-19) is caused by the SARS-CoV-2 coronavirus (SARS-CoV-2). SARS-CoV-2 entry requires transmembrane protease, serine 2 (TMPRSS2) to prime the initial spike protein. The cell's protease TMPRSS2 breaks open the virus's spike protein after a SARS-CoV-2 virion attaches to a target cell, revealing a fusion peptide.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V52794 | Aspirin-d4 (Acetylsalicylic Acid-d4; ASA-d4) | 97781-16-3 | Aspirin-d4 is the deuterium labelled form of Aspirin. |
|
V88342 | BZG2 | BZG2 is an allosteric inhibitor of SARS-CoV-2 main protease (Mpro) with IC50 of 77 µM. | |
|
V106310 | cTEV6-2 | cTEV6-2 binds to the cysteine residue (C151) of tobacco etch virus protease (TEV protease) and covalently inhibits TEV protease with an IC50 of 81.7 nM. | |
|
V52186 | DENV-IN-8 | 1809464-07-0 | DENV-IN-8 (Compound 5e) is a DENV2 inhibitor (antagonist) with EC50 of 0.068 μM. |
|
V52185 | DENV-IN-9 | 791838-63-6 | DENV-IN-9 (Compound 5f) is a DENV2 inhibitor (antagonist) with EC50 of 0.88 μM. |
|
V103625 | Dihydro K22 | 2926907-58-4 | Dihydro K22 is a derivative of the antiviral agent K22. |
|
V88223 | DV-B-120 | DV-B-120 is a competitive inhibitor of dengue virus (DENV) by inhibiting NS2B-NS3 protease, inhibiting DENV-1, DENV-2, DENV-3 and DENV-4 with IC50 of 5.35, 7.39, 10.49 and 8.58 μM, respectively. | |
|
V96972 | EBOV-IN-10 | 3040400-51-6 | EBOV-IN-10 is an orally active Ebola virus (EBOV) inhibitor with EC50 of 0.19 μM. |
|
V1907 | ESI-09 | 263707-16-0 | ESI-09 (ESI09) is a non-noncyclic nucleotide and specific inhibitor of exchange protein directly activated by cAMP (EPAC) with IC50 of 3.2 μM and 1.4 μM for EPAC1 and EPAC2, respectively. |
|
V83740 | FGA146 | ||
|
V54442 | Flaviviruses-IN-2 | 1009762-84-8 | Flaviviruses-IN-2 (compound 78) is a potent inhibitor of flaviviruses. |
|
V52973 | Flaviviruses-IN-3 | 420090-97-7 | Flaviviruses-IN-3 (compound 87) is a potent inhibitor of flaviviruses. |
|
V88341 | GZNL-P36 | GZNL-P36 is an orally active inhibitor of SARS-CoV-2 papain-like protease (PLpro) with an IC50 of 6.45 nM. | |
|
V104804 | HCV NS5B polymerase-IN-2 | 438476-59-6 | HCV NS5B polymerase-IN-2 (Compound 298) is a Ns5b polymerase inhibitor. |
|
V79718 | HCVcc-IN-1 | 2977251-08-2 | HCV (hepatitis C virus)cc-IN-2 is a benzothiazole-2-thiophene S-glycoside analogue with low toxicity and anti-viral effect. |
|
V78142 | HCVcc-IN-2 | 2977251-02-6 | HCV (hepatitis C virus)cc-IN-2 is a benzothiazole-2-thiophene S-glycoside analogue with antitumor and antiviral effect. |
|
V54446 | Herpes virus inhibitor 1 | 103424-73-3 | Herpes virus inhibitor 1 is a herpes virus inhibitor that disrupts the quaternary structure of herpes virus ribonucleotide reductase. |
|
V88338 | hrv 3c Protease | HRV 3C Protease is a protease derived from human rhinovirus. | |
|
V51886 | LabMol-301 | 1360243-08-8 | LabMol-301 inhibits the activity of NS5 RdRp and NS2B-NS3pro (IC50 of 0.8 and 7.4 μM, respectively). |
|
V51885 | LabMol-319 | 381188-63-2 | LabMol-319 is a potent Zika virus (ZIKV) NS5 RdRp inhibitor (antagonist) with IC50 of 1.6 μM. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
